Статья
Антикоагулянтная терапия при катетерной аблации фибрилляции и трепетания предсердий
Катетерная аблация (КА) фибрилляции и трепетания предсердий сопряжена с высоким риском как перипроцедуральных тромбоэмболических событий, так и кровотечений. Достаточная антикоагуляция является обязательной для снижения риска развития осложнений. Цель обзора — анализ современных подходов к антикоагулянтной терапии при КА фибрилляции и трепетания предсердий, а также предоставление практической информации на основании сравнения действующих рекомендаций и существующей доказательной базы. Проведен поиск литературных источников, посвященных антикоагулянтной терапии при КА, в базах данных PubMed, Scopus, Web of Science. Представлены результаты ключевых рандомизированных исследований и метаанализов, приведено сравнение текущих российских и международных рекомендаций. Обсуждены нерешенные вопросы, требующие проведения дальнейших исследований.
1. Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373-498. doi:10.1093/eurheartj/ehaa612.
3. Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019;321:1059-68. doi:10.1001/jama.2019.0335.
4. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1275-85. doi:10.1001/jama.2019.0692.
5. Kuck KH, Lebedev D, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace. 2021;23:362-9. doi:10.1093/europace/euaa298.
6. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial of atrial fibrillation. N Engl J Med. 2021;384:305-15. doi:10.1056/NEJMoa2029980.
7. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316-24. doi:10.1056/NEJMoa2029554.
8. Packer DL, Mark DB, Robb RA, et al. CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-74. doi:10.1001/jama.2019.0693.
9. Packer DL, Monahan KH, Al-Khalidi HR, et al. Ablation of Atrial Fibrillation in Heart Failure Patients: Additional outcomes of the CABANA Trial. Heart Rhythm. 2019;16(Suppl):S35. doi:10.1161/CIRCULATIONAHA.120.050991.
10. Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020;17:1057-65. doi:10.1016/j.hrthm.2020.02.030.
11. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1-160. doi:10.1093/europace/eux274.
12. Martin A-C, Godier A, Narayanan K, et al. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation. Understanding the Gaps in Evidence. Circulation. 2018;138:627-33. doi:10.1161/CIRCULATIONAHA.117.033326.
13. Goldi T, Krisai P, Knecht S, et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5:1406-14. doi:10.1016/j.jacep.2019.09.003.
14. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.
15. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management. Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation. 2014;129:2638-44. doi:10.1161/CIRCULATIONAHA.113.006426.
16. Konduru SV, Cheema AA, Jones РИ, et al. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol. 2012;35:277-84. doi:10.1007/s10840-012-9719-9.
17. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805-11. doi:10.1093/eurheartj/ehv177.
18. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376:1627-36. doi:10.1056/NEJMoa1701005.
19. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39:2942-55. doi:10.1093/eurheartj/ehy176.
20. Hohnloser SH, Camm J, Cappato R. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40:3013-21. doi:10.1093/eurheartj/ehz190.
21. Zhao Yu, Yang Yu, Tang X, et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017;267-82. doi:10.1007/s10840-016-0221-7.
22. Mao Y-J, Wang H, Huang P-F. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis. Pacing Clin Electrophysiol. 2020;43(10):1104-14. doi:10.1111/pace.14040.
23. Cardoso R, Knijnik L, Bhonsale A, et al. An updated metaanalysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018;15:107-15. doi:10.1016/j.hrthm.2017.09.011.
24. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility And Safety of uninterrupted peri-procedural Apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results From a Multicenter Study. Heart Rhythm. 2015;12(6):1162-8. doi:10.1016/j.hrthm.2015.02.028.
25. Bejinariu AG, Makimoto S, Wakili R, et al. One-year course of periprocedural anticoagulation in atrial fibrillation ablation: results of a German nationwide survey. Cardiology. 2020;145(10):676-81. doi:10.1159/000509399.
26. Reynolds MR, Allison JS, Natale A, et al. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation. The AEIOU Trial. JACC Clin Electrophysiol. 2018;4(5):580-8. doi:10.1016/j.jacep.2017.11.005.
27. Medi C, Evered L, Silbert B, et al. Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation. J Am Coll Cardiol. 2013;62:531-9. doi:10.1016/j.jacc.2013.03.073.
28. Schwarz N, Kuniss M, Nedelmann M, et al. Neuropsychological decline after catheter ablation of atrial fibrillation. Heart Rhythm. 2010;7:1761-7. doi:10.1016/j.hrthm.2010.07.035.
29. Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm. 2014;11(5):791-8. doi:10.1016/j.hrthm.2014.03.003.